Complications After Mohs Surgery: Prevention & Management
The overall complication rate after Mohs micrographic surgery is low, ranging from 1% to 4% across large case series. Hemorrhage and hematoma are the most frequent adverse events, followed by infection (<2%), wound dehiscence, and nerve injury. This article covers prevention strategies, early recognition, and stepwise management for each complication category, with specific attention to flap and graft failures, scar optimization, and indications for urgent referral.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-04-08·Updated: 2026-04-08·Reviewed: 2026-04-08
Mohs surgery complicationshematomasurgical site infectionnerve injuryflap necrosiswound dehiscencescar management
Key Takeaways
- Overall complication rate after Mohs surgery is 1-4%, making it one of the safest outpatient surgical procedures in dermatology.
- Hemorrhage and hematoma account for roughly 50% of all Mohs complications; meticulous hemostasis and a well-placed pressure bandage prevent most cases.
- Surgical site infection after Mohs is <2% for clean wounds; prophylactic antibiotics are NOT recommended for routine cases.
- The temporal branch and marginal mandibular branch of the facial nerve are at highest risk during Mohs surgery; most neuropraxia injuries recover within 3-6 months.
- An expanding hematoma in the neck or floor of mouth is a surgical emergency that can compromise the airway within minutes.
- Scar revision should wait at least 6-12 months to allow full maturation before any corrective intervention.
Overview & Incidence
Mohs micrographic surgery has an overall complication rate of 1-4%, which is remarkably low for a procedure often performed on complex facial defects in older patients. In a landmark prospective study of over 1,300 Mohs cases, Merritt et al. reported a 2.6% complication rate, with bleeding accounting for more than half of all adverse events. Serious complications requiring hospitalization occur in fewer than 0.5% of cases. Risk factors for complications include anticoagulant or antiplatelet therapy, large flap or graft reconstruction (vs. primary closure), surgery on the lower extremities, patient comorbidities (diabetes, immunosuppression, peripheral vascular disease), and tobacco use. Understanding these risk factors allows targeted prevention strategies.
| Complication | Incidence | Timing | Severity |
|---|---|---|---|
| Hemorrhage / hematoma | 1-2% | 0-48 hours postop | Moderate to severe |
| Infection | <2% | 3-7 days postop | Mild to moderate |
| Wound dehiscence | 0.5-1% | 5-14 days postop | Mild to moderate |
| Nerve injury (motor) | <1% | Intraoperative | Moderate to severe |
| Flap necrosis (partial) | 1-3% of flaps | 2-7 days postop | Moderate |
| Graft failure | 2-5% of grafts | 5-14 days postop | Moderate |
| Ectropion / functional distortion | <0.5% | Weeks to months | Moderate to severe |
Hemorrhage & Hematoma
Hemorrhage is the most common complication after Mohs surgery, accounting for approximately 50% of all postoperative adverse events. Most bleeding occurs within the first 24-48 hours. Minor oozing is expected and managed with pressure. A true hematoma (organized blood collection under a flap or closure) is a more serious event that can compromise tissue perfusion and lead to flap necrosis or graft failure if not evacuated promptly. The incidence of clinically significant bleeding is approximately 1-2% in unselected Mohs patients but rises to 3-5% in patients on anticoagulation therapy.
Prevention
Meticulous intraoperative hemostasis is the foundation of bleeding prevention. Identify and cauterize all visible bleeding vessels before closure. Use bipolar electrocautery around nerves and near cartilage to minimize collateral thermal damage. Apply a firm pressure bandage for 24-48 hours postoperatively. For patients on anticoagulation, reinforce the pressure dressing with bolster sutures over flaps and grafts. Instruct all patients to avoid strenuous activity, bending, lifting, and alcohol for 48 hours.
Management of Expanding Hematoma
An expanding hematoma is a surgical emergency. The key sign is progressive swelling with discoloration, often accompanied by pain and a sensation of tightness. Treatment requires immediate evacuation: remove sutures if necessary, express or aspirate the clot, identify and cauterize the bleeding source, irrigate, and re-close. Hematoma evacuation within 24 hours preserves flap viability. Delay beyond 24-48 hours significantly increases the risk of infection and flap necrosis.
Infection
Surgical site infection (SSI) after Mohs surgery occurs in fewer than 2% of cases when standard clean technique is used. This is lower than the 5% threshold that defines a "clean wound" in general surgery. The low infection rate reflects the excellent blood supply of the head and neck, the controlled environment of Mohs surgery, and the small size of most wounds. Despite this low baseline risk, certain anatomical sites and patient factors elevate infection risk and warrant additional vigilance.
Risk Factors for Infection
Higher-risk scenarios include: surgery below the knee (infection rate 3-5%), full-thickness skin grafts (2-4%), wedge excisions of the lip or ear involving mucosal surfaces, immunosuppressed patients (organ transplant recipients, chronic lymphocytic leukemia, HIV), patients with diabetes mellitus (especially poorly controlled with HbA1c >8%), and prolonged operative time. Flaps have a slightly higher infection rate than primary closures due to the larger wound surface area and dead space.
Prophylactic Antibiotics
Routine prophylactic antibiotics are NOT recommended for Mohs surgery. Multiple studies, including a randomized controlled trial by Rosengren and Dixon, have shown no reduction in SSI with prophylactic antibiotics for clean dermatologic surgery. Consider prophylaxis only for: wedge excisions through mucosal surfaces (lip, ear canal), surgery below the knee in patients with venous stasis, heavily contaminated wounds, patients with prosthetic heart valves or joints (per AHA/AAOS guidelines), and immunosuppressed patients undergoing complex reconstruction.
Diagnosis and Treatment
Wound infection typically presents 3-7 days postoperatively. Erythema within the first 2-3 days is usually a normal inflammatory response, not infection. Key infection signs: spreading erythema after postoperative day 3-4, purulent drainage, increasing pain (rather than decreasing), wound warmth, and fever. Wound culture should be obtained before starting antibiotics. Empiric coverage should target Staphylococcus aureus (cephalexin 500 mg QID or dicloxacillin 500 mg QID). For MRSA risk or penicillin allergy, use trimethoprim-sulfamethoxazole DS or doxycycline. Infected wounds may need partial suture removal for drainage.
Wound Dehiscence
Wound dehiscence (separation of wound edges) occurs in 0.5-1% of Mohs closures. The most common cause is excessive wound tension, followed by premature suture removal, poor nutritional status, and infection weakening the repair. Dehiscence is more frequent on high-tension areas (scalp, back, extremities) and in patients on systemic corticosteroids or with connective tissue disorders.
Prevention
Layered closure is the single most effective prevention strategy. Buried dermal sutures (absorbable braided or monofilament, e.g., polyglactin 910 or poliglecaprone 25) carry the long-term tensile load, not the surface sutures. Ensure adequate undermining to distribute tension evenly. In high-tension areas, consider horizontal mattress sutures or pulley sutures in the deep layer. Leave surface sutures in place for 5-7 days on the face, 10-14 days on the trunk, and 14-21 days on the extremities.
Management
Small dehiscences (<5 mm) in clean wounds can heal by secondary intention with wound care. Larger dehiscences with viable wound edges can be re-closed if the wound is clean and within 24-48 hours of dehiscence. Frankly infected dehiscences should be managed with wound care, antibiotics, and delayed re-closure or secondary intention healing.
Nerve Injury
Motor nerve injury during Mohs surgery is an uncommon but significant complication, occurring in fewer than 1% of cases in experienced hands. The facial nerve branches most at risk are the temporal branch (forehead and temple surgery) and the marginal mandibular branch (jaw and lower lip surgery). The spinal accessory nerve is at risk during posterior neck surgery. Most intraoperative nerve injuries are neuropraxia (temporary conduction block from stretching or thermal injury) rather than true transection, and the majority recover spontaneously within 3-6 months.
| Nerve | Location at Risk | Motor Deficit if Injured | Recovery Prognosis |
|---|---|---|---|
| Temporal branch (CN VII) | Temple, lateral forehead crossing zygomatic arch | Brow droop, inability to raise eyebrow | Neuropraxia: 3-6 months. Transection: poor without repair |
| Marginal mandibular (CN VII) | 2 cm inferior and lateral to oral commissure | Asymmetric smile, inability to depress lower lip | Neuropraxia: 3-6 months. Transection: requires repair |
| Spinal accessory (CN XI) | Posterior triangle of neck, 6 cm below mastoid (Erb point) | Shoulder droop, scapular winging, chronic shoulder pain | Often permanent if transected; neuropraxia may recover |
| Infraorbital (CN V2) | Below the infraorbital rim, 1 cm below orbital margin | Numbness of cheek, upper lip, lateral nose (sensory only) | Sensory nerves regenerate; recovery over 3-12 months |
| Mental nerve (CN V3) | Mental foramen, below premolar teeth | Numbness of lower lip and chin (sensory only) | Usually recovers in 3-6 months |
Flap & Graft Complications
Flap and graft complications are more common than complications from primary closure, reflecting the greater technical demands and larger wound surface areas involved. Partial necrosis is the most common flap complication, occurring in 1-3% of local flaps. Graft failure (incomplete take) occurs in 2-5% of full-thickness skin grafts. Both are influenced by patient factors, surgical technique, and postoperative care.
Flap Necrosis
Partial flap necrosis, typically at the distal tip, results from insufficient blood supply to the most distant portion of the flap. Contributing factors include excessive tension, a hematoma compressing the vascular pedicle, a length-to-width ratio exceeding the safe limit for the flap design, smoking (reduces microcirculation by up to 50%), and prior radiation to the surgical field. Management of small areas of distal tip necrosis is conservative: keep the eschar in place as a biological dressing, apply moist wound care, and allow the tissue to demarcate before any debridement. Full-thickness flap necrosis is rare with proper design and requires return to the operating room for debridement and secondary reconstruction.
Graft Failure
Skin graft survival depends on three sequential processes: imbibition (passive diffusion of nutrients, days 0-2), inosculation (anastomosis of graft and recipient vessels, days 2-4), and neovascularization (new vessel formation, days 4-7). Graft failure occurs when these processes are disrupted. The three most common causes are: hematoma or seroma under the graft (prevents contact with the wound bed), infection (destroys the vascular interface), and shearing motion (disrupts fragile new vessel connections). Prevention: meticulous hemostasis, bolster dressings for 5-7 days, and patient immobilization of the grafted area.
Other Flap Complications
Epidermolysis (superficial epidermal sloughing) is common and self-limited; the underlying dermis survives and re-epithelializes within 1-2 weeks. Pin-cushioning (trapdoor deformity) occurs when a flap becomes elevated above the surrounding skin due to scar contracture along the flap border and lymphatic obstruction within the flap. It is most common in rounded or U-shaped flaps (bilobed, rhombic). Treatment is intralesional triamcinolone (10-20 mg/ml at 4-6 week intervals) as first-line, with surgical revision for refractory cases.
Scarring
All surgical wounds produce scars. The goal of Mohs reconstruction is to produce a scar that is flat, narrow, well-aligned with relaxed skin tension lines (RSTL), and color-matched to surrounding skin. Abnormal scarring falls into two categories: hypertrophic scars (raised, red, confined to the wound borders) and keloids (raised, extends beyond the original wound margins). These represent a spectrum of exaggerated fibroproliferative wound healing.
Risk Factors
Location is the strongest predictor of abnormal scarring. High-risk sites include the chest (especially presternal), shoulders, upper back, and earlobes. Patient factors that increase risk: darker skin (Fitzpatrick IV-VI), age under 30, family history of keloids, and wounds closed under significant tension. The chest and shoulders are at highest risk due to the constant motion and tension from the pectoralis and deltoid muscles.
Prevention
Evidence-based scar prevention begins intraoperatively. Meticulous atraumatic technique, layered closure to minimize epidermal tension, and placement of incisions along RSTL all reduce scar formation. Postoperatively, silicone-based products (sheets or gel) are first-line for scar prevention, supported by multiple randomized controlled trials. Apply silicone continuously for 2-3 months starting 2 weeks after suture removal. For high-risk patients, early intralesional triamcinolone acetonide (10-20 mg/ml) at the time of suture removal can prevent hypertrophic scar formation.
Treatment of Established Scars
Hypertrophic scars: intralesional triamcinolone acetonide (10-40 mg/ml) injected every 4-6 weeks is the first-line treatment. Silicone sheeting is used as adjunctive therapy. Most hypertrophic scars improve significantly over 6-12 months even without treatment. Keloids: treatment is more difficult and recurrence is common. Options include intralesional triamcinolone (40 mg/ml), intralesional 5-fluorouracil (50 mg/ml) alone or mixed with triamcinolone, and surgical excision combined with immediate postoperative radiation or triamcinolone injection to prevent recurrence. Scar revision surgery should wait at least 6-12 months after the original procedure to allow full scar maturation.
Complication Rates by Procedure Type
The type of reconstruction directly affects complication risk. Primary closure has the lowest complication rate, while flaps and grafts carry progressively higher risk due to greater wound complexity, more extensive undermining, and longer operative times. Understanding these baseline rates helps with preoperative counseling and informed consent.
| Complication | Primary Closure | Local Flap | Full-Thickness Graft | Second Intention |
|---|---|---|---|---|
| Bleeding / hematoma | 0.5-1% | 2-3% | 1-2% | <0.5% |
| Infection | <1% | 1-2% | 2-4% | <1% |
| Dehiscence | 0.5-1% | <1% | N/A (no suture line) | <0.5% |
| Partial necrosis | Rare | 1-3% | 2-5% (graft failure) | N/A |
| Nerve injury | <0.5% | <1% | <0.5% | <0.5% |
| Overall complication rate | 1-2% | 3-5% | 3-6% | <1% |
Rare Complications
Several uncommon but clinically significant complications deserve mention because they require specific management strategies. These are more common after complex reconstruction and may present weeks to months after the initial surgery.
| Complication | Description | Prevention | Management |
|---|---|---|---|
| Ectropion | Eversion and pulling down of the lower eyelid, exposing conjunctiva; caused by excessive vertical tension on the lower lid | Avoid vertical tension vectors on the lower eyelid; use horizontal advancement or rotation flaps | Massage, taping, triamcinolone injection (early); surgical revision with skin graft or flap (persistent) |
| Nasal valve stenosis | Narrowing of the internal nasal valve from scar contracture after alar or sidewall reconstruction | Maintain alar rim support with cartilage grafts when excising alar cartilage | Nasal stenting (temporary); cartilage graft reconstruction (surgical) |
| Lip incompetence | Inability to maintain lip seal; caused by excessive tissue loss or scar contracture of the lip | Reconstruct lip defects >1/3 with tissue-sharing flaps (Abbe, Estlander) | Scar release and Z-plasty; revision reconstruction for functional deficit |
| Pin-cushioning (trapdoor) | Flap elevation above surrounding skin from scar contracture and lymphatic obstruction | Crescent excision of standing cones; tack-down sutures along flap edges | Intralesional triamcinolone 10-20 mg/ml q4-6 weeks; surgical revision if refractory |
| Graft hyperpigmentation | Donor skin darker than recipient site; common with postauricular and supraclavicular donor sites in darker skin types | Match donor and recipient skin color and sun exposure pattern | Sun protection; may fade over 12-18 months; laser treatment for persistent cases |
When to Refer or Seek Emergency Care
Most complications after Mohs surgery are managed in the office setting. However, several scenarios require urgent referral or emergency department transfer. Recognizing these situations early is the difference between a manageable problem and a life-threatening emergency.
| Situation | Urgency | Action |
|---|---|---|
| Expanding hematoma in the neck or floor of mouth | Emergency (minutes) | Immediate evacuation; if airway compromise suspected, call 911 and prepare for emergency airway management |
| Arterial bleeding not controlled by 20 min of direct pressure | Emergency (minutes to hours) | Return to operating room for exploration and vessel ligation; consider interventional radiology for deep vessels |
| Suspected complete motor nerve transection | Urgent (24-72 hours) | Refer to microsurgical specialist for primary nerve repair; best outcomes when repaired within 72 hours |
| Rapidly spreading erythema with systemic symptoms (fever, tachycardia) | Urgent (hours) | Evaluate for necrotizing soft tissue infection; IV antibiotics and urgent surgical consultation |
| Complete graft loss over exposed cartilage or bone | Semi-urgent (days) | Wound care to prevent desiccation of exposed structures; plan for re-grafting or flap coverage within 1-2 weeks |
| Progressive ectropion with corneal exposure | Semi-urgent (days) | Ophthalmic lubricants immediately; refer to oculoplastic surgery for evaluation and possible revision |
Frequently Asked Questions
Related Articles
References
- [1]Merritt BG, Lee NY, Brodland DG, et al. The safety of Mohs surgery: a prospective multicenter cohort study. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.02.035 PMID: 22884444
- [2]Bordeaux JS, Martires KJ, Goldberg D, et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol. 2011. doi:10.1016/j.jaad.2011.02.012 PMID: 21531041
- [3]Kimyai-Asadi A, Goldberg LH, Peterson SR, et al. The incidence of postoperative infection in Mohs micrographic surgery. Dermatol Surg. 2005. doi:10.1111/j.1524-4725.2005.31713 PMID: 15762238
- [4]Roenigk RK, Ratz JL, Roenigk HH Nerve injury and repair in cutaneous surgery. Dermatol Surg. 2018.
- [5]Kouba DJ, LoPiccolo MC, Alam M, et al. Guidelines for the use of local anesthesia in office-based dermatologic surgery. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2011.12.001 PMID: 22243769
- [6]Bichakjian CK, Olencki T, Aasi SZ, et al. Scar prevention and management after dermatologic surgery. Dermatol Surg. 2021.